Pfizer – Price Restraint/Access and Affordability (2005 – 2006)
Increasing Access to Pfizer Products RESOLVED: Shareholders request the Board of Directors report by September 2006 on measures Pfizer is taking to contain the price increases of its most-prescribed drugs to levels equal to or below the annual rate of inflation. SUPPORTING STATEMENT: Enacting this proposal will align our company with its previously stated practice on prescription drug price increases. Access to pharmaceutical products is essential for adequate health care for all Americans; we believe that restraining price increases is an effective way to expand access to pharmaceutical products. In 2002, Pfizer stated: “Over the past decade, after accounting for …
Dow Chemical – Report on Certain Toxic Chemicals From Dow Chemical Products Widely Detected in Humans (2004 – 2005)
Company: Dow Chemical Final Vote: 7.7% Year: 2004-2005 …
General Electric – Disclosure of Costs of Delay of Cleanup of Toxic Sites (2004 – 2005)
Company: General Electric Final Vote: 27.5 Year: 2004-2005 …
General Electric – Report on Meeting Public Interest Broadcasting Obligations (2004 – 2005)
2004-2005 Final Vote: Omitted …
Recent Comments